These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11966945)

  • 1. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
    Crowley S; Tognarini D; Desmond P; Lees M; Saal G
    J Gastroenterol Hepatol; 2002 Feb; 17(2):153-64. PubMed ID: 11966945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
    Arnold E; Yuan Y; Iloeje U; Cook G
    Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
    Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.
    Orlewska E
    Value Health; 2002; 5(5):405-21. PubMed ID: 12201858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.
    Brooks EA; Lacey LF; Payne SL; Miller DW
    Am J Manag Care; 2001 Jul; 7(7):677-82. PubMed ID: 11464426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B.
    Crowley SJ; Tognarini D; Desmond PV; Lees M
    Pharmacoeconomics; 2000 May; 17(5):409-27. PubMed ID: 10977384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
    Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
    Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom.
    Veenstra DL; Sullivan SD; Dusheiko GM; Jacobs M; Aledort JE; Lewis G; Patel KK
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):631-8. PubMed ID: 17625431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
    Lacey LF; Gane E
    J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
    Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
    Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
    Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
    Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
    Takeda A; Jones J; Shepherd J; Davidson P; Price A
    J Viral Hepat; 2007 Feb; 14(2):75-88. PubMed ID: 17244247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness.
    Wong JB
    Acta Gastroenterol Belg; 1998; 61(2):238-42. PubMed ID: 9658620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.
    Saab S; Ham MY; Stone MA; Holt C; Tong M
    Liver Transpl; 2009 Apr; 15(4):413-20. PubMed ID: 19326401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.